I-Mab reported positive Phase 1b study results for givastomig in metastatic gastric cancers, highlighting significant efficacy and a favorable safety profile. I-Mab has announced positive results from ...
Sebetralstat has a compelling drug profile for the on-demand treatment of HAE attacks and could become the new standard of care in a billion-dollar market opportunity. KalVista is transitioning to a ...
X4 Pharmaceuticals announced the acceptance of two abstracts for presentation at the upcoming European Hematology Association Congress regarding the positive results from their Phase 2 trial of ...
Hosted on MSN
Kymera Therapeutics soars 35% on positive phase 1 results for oral STAT6 degrader KT-621
Kymera Therapeutics (NASDAQ:KYMR) Monday reported positive Phase 1 results from its healthy volunteer study of KT-621, a first-in-class oral STAT6 degrader, sending shares up +35% in premarket trading ...
Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback